How Is Gastroparesis Monitored After Ozempic Use?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Concerns

If you're experiencing persistent nausea, vomiting, or abdominal bloating after taking Ozempic, you may be concerned about gastroparesis. This condition, which slows stomach emptying, requires careful clinical monitoring and follow-up testing to manage effectively. The historical context of diabetes treatments has evolved to include GLP-1 receptor agonists, and understanding their side effects is crucial for patient safety. This page explains the key monitoring tests and follow-up protocols for Ozempic-associated gastroparesis.

Find Out If You Qualify for Compensation →

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects. However, this mechanism also underlies the gastrointestinal adverse reactions commonly reported with its use. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight the dose-dependent nature of gastrointestinal effects.

Mechanistic Pathway and Risk of Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves its action on GLP-1 receptors in the gastrointestinal tract, which slows gastric emptying. While this effect is intended to improve glycemic control, it can become pathological in some patients, leading to symptomatic gastroparesis. The timeline between exposure and documented harm varies; gastrointestinal symptoms often emerge during dose escalation, but the development of clinically significant gastroparesis may require prolonged exposure. Patients who experience persistent nausea, vomiting, or abdominal pain should undergo evaluation for gastroparesis. Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a potential adverse effect. The label notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported, and that anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of this potential risk. This gap in labeling could be relevant in legal contexts, as patients may argue that they were not adequately informed of the risk.

Legal Considerations for Ohio Patients

For affected patients in Ohio, attorney-related considerations include the statute of limitations for filing a product liability claim. In Ohio, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For claims involving harm from Ozempic, this means that patients must file within two years of recognizing that their gastroparesis may be linked to the medication. The timeline between exposure and harm is crucial: if symptoms develop gradually, the discovery date may be later than the initial exposure. Patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances. In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which can progress to gastroparesis in susceptible individuals. The prescribing information does not explicitly warn about gastroparesis, potentially leaving patients uninformed. Ohio patients who develop gastroparesis after using Ozempic should be aware of the two-year statute of limitations and seek legal advice promptly.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Ohio?

In Ohio, the statute of limitations for personal injury claims, including those related to Ozempic and gastroparesis, is generally two years from the date the injury was discovered or should have been discovered. Patients should consult with an attorney to determine their specific filing deadline.

Does Ozempic's prescribing information warn about gastroparesis?

No, the prescribing information for Ozempic does not explicitly list gastroparesis as a potential adverse effect. It includes warnings about gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but does not specifically mention gastroparesis. This lack of explicit warning may be relevant in legal contexts.

What are the common gastrointestinal side effects of Ozempic?

Common gastrointestinal side effects of Ozempic include nausea (up to 20.3%), vomiting (up to 9.2%), diarrhea (up to 8.8%), abdominal pain (up to 7.3%), and constipation (up to 5.0%). These effects are dose-dependent and often occur during dose escalation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.